



## **Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series**

October 21, 2025

SAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in Citi's SMID Biotech C-Suite Fireside Chat Series on Thursday, October 23, 2025, at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time.

A live audio webcast of the discussion will be available [here](#) or by visiting the Investors & Media section of Biomea's website at <https://investors.biomeafusion.com/news-events/events>. A replay of the webcast will be available following the live event.

### **About Biomea Fusion**

Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world's population. Biomea's mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.

Visit us at [biomeafusion.com](https://biomeafusion.com) and follow us on [LinkedIn](#), [X](#) and [Facebook](#).

### **Contact:**

Meichiel Jennifer Weiss  
Sr. Director of Investor Relations and Corporate Development  
[ir@biomeafusion.com](mailto:ir@biomeafusion.com)